South Africa Smoking Cessation and Engagement in HIV/TB Care Care
Launched by MASSACHUSETTS GENERAL HOSPITAL · Apr 24, 2023
Trial Information
Current as of August 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the South Africa Smoking Cessation and Engagement in HIV/TB Care study, is focused on helping people who are living with HIV and/or tuberculosis (TB) quit smoking. Researchers are testing a new program called QUIT-AD, which combines existing methods to improve the chances of quitting smoking and achieving better health outcomes for those undergoing treatment for HIV and TB. The goal is to see if this program is easy to use, accepted by participants, and effective in helping them stop smoking, which can lead to better overall health.
To be eligible for this study, participants need to be at least 18 years old, willing to provide consent, and either living with HIV and on treatment or recently starting TB treatment. They should also smoke more than five cigarettes a day and be motivated to quit smoking. However, those who use other tobacco products, have certain untreated mental health issues, or are currently receiving other smoking cessation treatments cannot participate. If you join the study, you can expect support and resources to help you quit smoking while managing your health conditions. This trial could potentially improve health outcomes for many individuals in South Africa.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged 18 or older
- • 2. Willing and able to provide written informed consent
- • 3. Living with HIV, confirmed via medical record, and on antiretroviral therapy (ART) AND/OR within 1 month of initiating or reinitiating TB treatment; positive GeneXpert test or sputum culture
- • (5) Daily smoker operationalized as \> 5 cigarettes per day, (6) Motivation (\> 5/10) to quit smoking or \> 24 hour quit past yr
- Exclusion Criteria:
- • 1. Habitual use of other tobacco products
- • 2. Current interfering untreated/unstable mental health condition (e.g., psychosis, bipolar dx)
- • 3. Current use of non-study pharmacotherapy for smoking cessation,
- • 4. Cognitive Behavioral Therapy for smoking cessation initiated within the past year,
- • 5. Diagnosed with extra-pulmonary or drug resistant (MDR or XDR) TB based upon chart review
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rondebosch, , South Africa
Patients applied
Trial Officials
Amelia Stanton, PhD
Principal Investigator
Boston University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported